C-RAD, a global leader in SGRT, announces today that the Board and CEO Cecilia de Leeuw have agreed that she will step down from the CEO role. Furthermore, the board has decided to appoint the company's CFO Linda Frölén acting CEO. Johan Danielsson, who has successfully built the global service business, is appointed deputy CEO. Board member Peter Simonsbacka is engaged on a consulting basis two days a week to accelerate the level of activity. The board will immediately begin recruiting a new CEO.
The board and Cecilia de Leeuw, who has been CEO since December 2022, have jointly agreed that it is time to hand over leadership. CFO Linda Frölén is appointed acting CEO. Johan Danielsson, who has successfully developed and grown the global service business, is appointed deputy CEO. Peter Simonsbacka, who is a board member and previously Chief Commercial Officer at AddLife, is engaged on a consulting basis two days a week. Together, the three form an executive management team. The board has engaged Alumni Global to recruit a new CEO.
"On behalf of the board, I would like to thank Cecilia for her great commitment and good work in developing the company, the organization and the profitability", comments Chairwoman Kristina Willgård.
"It is time to hand over the leadership, and it has been a fantastic three years. We have good momentum in our customer dialogues around the world, clinics place great value on C-RADs SGRT technology that improves the quality of life for cancer patients worldwide. I want to thank our amazing team. Thank you and keep up the important work you do every day", comments Cecilia de Leeuw.
For information please contact:
Kristina Willgård, Chairwoman of the Board of C-RAD
About C-RAD
C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.
C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit http://www.c-rad.com
This information is information that C-Rad is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-10-21 18:15 CEST.